Zai Lab Limited has announced plans for a pivotal clinical trial of ZL-1310, a Delta-like ligand 3 (DLL3) antibody-drug conjugate $(ADC)$, aimed at treating patients with extensive-stage small cell lung cancer (ES-SCLC). The company intends to begin the randomized registrational study later this year, comparing the selected dose of ZL-1310 against the current standard of care for second-line treatment. This follows updated data from an ongoing global Phase 1a/1b trial, which demonstrated a favorable safety profile and promising efficacy. Additionally, Zai Lab is actively enrolling patients in a front-line SCLC study and in other neuroendocrine carcinomas, with further data updates anticipated in the coming months. An investor conference call and webcast to discuss these developments is scheduled for June 2, 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。